ELI LILLY & Co (LLY) operating KPIs
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Eli Lilly trajenta (linagliptin) — Worldwide revenue ($M) [legacy separate disclosure] ($M)
Form 10-Q / 10-K Note 2 & MD&A (legacy separate product disclosure prior to FY2025 reorganization)
Latest, Q3 2024
91.7
Period ended Sep 30, 2024
Change on a year earlier
-3.7%
95.2 in Q3 2023
History
33 quarters
Since Q1 2014
Sources
27
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Trajenta (linagliptin) — Worldwide revenue ($M) [legacy separate disclosure] ($M) | Year on year | Source |
|---|---|---|---|---|
| Q3 2024 | Sep 30, 2024 | 91.7 | -3.7% | Form 10-Q (filed 2024-10-30) ↗ |
| Q2 2024 | Jun 30, 2024 | 76.6 | -26.1% | Form 10-Q (filed 2024-08-08) ↗ |
| Q1 2024 | Mar 31, 2024 | 88.9 | +3.6% | Form 10-Q (filed 2024-04-30) ↗ |
| Q4 2023 | Dec 31, 2023 | 102 | +12.7% | Form 10-K (filed 2024-02-21) ↗ |
| Q3 2023 | Sep 30, 2023 | 95.2 | -8.3% | Form 10-Q (filed 2024-10-30) ↗ |
| Q2 2023 | Jun 30, 2023 | 104 | +6.7% | Form 10-Q (filed 2024-08-08) ↗ |
| Q1 2023 | Mar 31, 2023 | 85.8 | -6.7% | Form 10-Q (filed 2024-04-30) ↗ |
| Q4 2022 | Dec 31, 2022 | 90.7 | -2.1% | Form 10-K (filed 2024-02-21) ↗ |
| Q3 2022 | Sep 30, 2022 | 104 | +8.0% | Form 10-Q (filed 2023-11-02) ↗ |
| Q2 2022 | Jun 30, 2022 | 97.1 | +8.9% | Form 10-Q (filed 2023-08-08) ↗ |
| Q1 2022 | Mar 31, 2022 | 92 | -2.7% | Form 10-Q (filed 2023-04-27) ↗ |
| Q4 2021 | Dec 31, 2021 | 92.6 | -4.3% | Form 10-K (filed 2024-02-21) ↗ |
| Q3 2021 | Sep 30, 2021 | 96.1 | +4.8% | Form 10-Q (filed 2022-11-01) ↗ |
| Q2 2021 | Jun 30, 2021 | 89.2 | +16.1% | Form 10-Q (filed 2022-08-04) ↗ |
| Q1 2021 | Mar 31, 2021 | 94.6 | +1.5% | Form 10-Q (filed 2022-04-29) ↗ |
| Q4 2020 | Dec 31, 2020 | 96.8 | -35.1% | Form 10-K (filed 2023-02-22) ↗ |
| Q3 2020 | Sep 30, 2020 | 91.7 | -41.0% | Form 10-Q (filed 2021-10-27) ↗ |
| Q2 2020 | Jun 30, 2020 | 76.8 | -50.1% | Form 10-Q (filed 2021-08-03) ↗ |
| Q1 2020 | Mar 31, 2020 | 93.2 | -29.3% | Form 10-Q (filed 2021-04-30) ↗ |
| Q4 2019 | Dec 31, 2019 | 149 | -4.5% | Form 10-K (filed 2022-02-23) ↗ |
| Q3 2019 | Sep 30, 2019 | 156 | +14.6% | Form 10-Q (filed 2020-10-28) ↗ |
| Q2 2019 | Jun 30, 2019 | 154 | +8.6% | Form 10-Q (filed 2020-07-31) ↗ |
| Q1 2019 | Mar 31, 2019 | 132 | -6.5% | Form 10-Q (filed 2020-05-01) ↗ |
| Q4 2018 | Dec 31, 2018 | 156 | +20.4% | Form 10-K (filed 2021-02-17) ↗ |
| Q3 2018 | Sep 30, 2018 | 136 | -11.5% | Form 10-Q (filed 2019-10-25) ↗ |
| Q2 2018 | Jun 30, 2018 | 142 | -0.1% | Form 10-Q (filed 2019-08-02) ↗ |
| Q1 2018 | Mar 31, 2018 | 141 | +24.9% | Form 10-Q (filed 2019-05-02) ↗ |
| Q4 2017 | Dec 31, 2017 | 130 | – | Form 10-K (filed 2020-02-19) ↗ |
| Q3 2017 | Sep 30, 2017 | 153 | – | Form 10-Q (filed 2018-11-06) ↗ |
| Q2 2017 | Jun 30, 2017 | 142 | – | Form 10-Q (filed 2018-07-25) ↗ |
| Q1 2017 | Mar 31, 2017 | 113 | – | Form 10-Q (filed 2018-04-27) ↗ |
| Q1 2015 | Mar 31, 2015 | 82.3 | +7.0% | Form 10-Q (filed 2015-04-30) ↗ |
| Q1 2014 | Mar 31, 2014 | 76.9 | – | Form 10-Q (filed 2015-04-30) ↗ |
Breakdown
What makes up trajenta (linagliptin) — worldwide revenue ($m) [legacy separate disclosure]
Cite this data
StockData. (2026). Eli Lilly Trajenta (linagliptin) — Worldwide revenue ($M) [legacy separate disclosure] ($M), quarterly Q1 2014–Q3 2024 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med_trajenta_ww
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.